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Mechanically-induced skeletal muscle growth is regulated by mammalian/mechanistic target of
rapamycin complex 1 (mTORC1). Yes-Associated Protein (YAP) is a mechanically-sensitive, and
growth-related, transcriptional co-activator that can regulate mTORC1. Here we show that, in skele-
tal muscle, mechanical overload promotes an increase in YAP expression; however, the time course
of YAP expression is markedly different from that of mTORC1 activation. We also show that the
overexpression of YAP induces hypertrophy via an mTORC1-independent mechanism. Finally, we
provide preliminary evidence of possible mediators of YAP-induced hypertrophy (e.g. increased
MyoD and c-Myc expression, and decreased Smad2/3 activity and muscle ring ﬁnger 1 (MuRF1)
expression).
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The Yes-Associated Protein (YAP) is a cell growth-related tran-
scriptional co-activator that is, in part, regulated by the Hippo sig-
naling network [1]. More speciﬁcally, YAP can be phosphorylated
by the large tumor suppressor kinases 1 and 2 (LATS1/2) which
serve as the terminal kinases of the Hippo pathway. The phospho-
rylation of YAP on the serine 112 residue (S112; S127 in humans)
by LATS1/2 leads to its exclusion from the nucleus, and thus, areduction in its activity as a transcriptional co-activator [2]. In its
active form, YAP binds and co-activates a range of transcription
factors including the TEA domain (TEAD) transcription factors
[3]. Active TEAD transcription factors can, in turn, regulate the
expression of genes in various tissues by binding to promoters that
contain MCAT (muscle C, A, and T) and A/T-rich sites [4,5]. Thus,
YAP has the potential to regulate cell growth-related gene expres-
sion and signaling in multiple cell types.
YAP has recently been implicated in the transduction of
mechanical signals (i.e., mechanotransduction) that regulate vari-
ous processes including cellular growth (for review see [6]). For
instance, it was recently shown that mechanical stretch-induced
increases in cell proliferation are associated with an in increase
the amount of nuclear YAP [7]. Moreover, recent studies have
found that YAP not only regulates proliferation, but it can also reg-
ulate cell size by increasing the activity of the mammalian/mecha-
nistic target of rapamycin complex 1 (mTORC1) [8]. The effects of
YAP on mTORC1 are particularly intriguing because signaling by
mTORC1 has also been widely implicated in the mechanical
regulation of skeletal muscle growth [9]. For instance, subjecting
muscles to chronic mechanical overload results in an
mTORC1-dependent increase in muscle ﬁber size (i.e., hypertro-
phy) [9,10]. Thus, based on the studies which have shown that
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regulate mTORC1 signaling, we reasoned that YAP might play a
role in the mechanical activation of mTORC1 and skeletal muscle
growth. Therefore, the goal of this study was to explore these
possibilities.
2. Materials and methods
Extended Materials and Methods are provided in the accompa-
nying Supplementary material.
2.1. Animals
Male and female FVB/N mice, 8–10 weeks old, were housed
under a 12-h light/dark cycle with ad libitum access to food and
water unless otherwise stated. Before all surgical procedures, mice
were anaesthetized with an intraperitoneal injection of ketamine
(100 mg/kg) and xylazine (10 mg/kg). After tissue extraction, the
mice were euthanized by cervical dislocation. All methods were
approved by the Institutional Animal Care and Use Committee of
the University of Wisconsin-Madison.
2.2. Synergist ablation surgery
Male mice were subjected to bilateral synergist ablation (SA)
surgeries which involved removing the soleus and distal half of
the gastrocnemius muscle as previously described [10–12].
2.3. Plasmid constructs and puriﬁcation
All plasmid DNA constructs and amounts used for
co-transfection in this study are listed in Supplementary Table 1.
Plasmid DNA was ampliﬁed in DH5a Escherichia coli, puriﬁed with
an EndoFree plasmid kit (Qiagen, Valencia, CA, USA), and resus-
pended in sterile PBS as previously described [13,14].
2.4. In vivo transfection via electroporation
Sterile plasmid DNA was transfected into Tibialis Anterior (TA)
muscles of female mice by electroporation as described previously
[13,14].
2.5. Rapamycin injections
Rapamycin was purchased from LC laboratories (Woburn, MA,
USA) and was dissolved in DMSO to generate a 5 lg/lL stock solu-
tion. The appropriate volume of the stock solution needed to inject
mice with 1.5 mg/kg of rapamycin was dissolved in 200 lL of PBS.
For the vehicle control condition, mice were injected with an
equivalent amount of DMSO dissolved in 200 lL of PBS.
Immediately following electroporation the vehicle or rapamycin
solutions were administered via intraperitoneal injections, and
these injections were repeated every 24 h for 7 days.
2.6. Western blotting
Muscle protein samples were prepared and subjected to
Western blot analysis as previously described [10]. Speciﬁc anti-
bodies that were used are described in the Supplementary
Materials and Methods.
2.7. Immunohistochemical analysis of muscle ﬁber cross-sectional area
Transfected TA muscles were dissected, cut and processed for
immunohistochemical staining and quantiﬁcation of muscle ﬁber
cross-sectional area (CSA) as previously described [14]. Speciﬁcantibodies used are described in the Supplementary Materials
and Methods.
2.8. Statistical analysis
All values are expressed as means (+S.E.M. in graphs). Student’s
2-tailed unpaired t-tests were used for all 2-group comparisons.
Time course data were analyzed using a one-way ANOVA followed
by a Newman–Keuls post hoc test. Four group comparisons were
performed using a two-way ANOVA followed by a Bonferroni post
hoc analysis. Differences between groups were considered signiﬁ-
cant if P < 0.05. All data analysis was performed using GraphPad
Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA).3. Results
3.1. Mechanical overload induces an increase in the expression of YAP
To determine whether the expression of YAP is sensitive to
increased mechanical loading, we utilized the synergist ablation
(SA) model [10]. SA places a chronic mechanical overload on the
Plantaris muscle which results in a progressive increase in muscle
mass over 10–14 days (e.g. see [12,15]). As shown in Fig. 1A and B,
SA induced a progressive increase in the protein levels of total YAP
protein with a peak (4.5-fold) occurring at 7 days following the
onset of SA. Similarly, Yap phosphorylation on the serine 112
residue [P-YAP(S112)] was also increased by SA but no
signiﬁcant change in the YAP phospho to total ratio was detected
(Fig. 1A). These data show that YAP expression and the Hippo
signaling pathway are both sensitive to increased mechanical load-
ing in skeletal muscle. We next examined the effect of SA on
mTORC1 signaling as measured by changes in the phosphorylation
of p70S6k1 on the threonine 389 residue [P-p70S6k1(T389)]. The
results from these analyses revealed that SA induced a relatively
rapid increase in mTORC1 signaling that peaked at day 2
(14-fold) and then slowly declined between days 4 and 14
(Fig. 1A and B). The different temporal effects of SA on total YAP
and mTORC1 signaling indicate that there is not a simple relation-
ship between the activation of mTORC1 and changes in total YAP
expression under these conditions. This is further highlighted by
our ﬁnding that the SA-induced increase in c-Myc, whose expres-
sion is known to be positively regulated by YAP [16–21], also dis-
plays a different temporal pattern to YAP and mTORC1 signaling
(Fig. 1A).
In addition its potential role in the regulation of mTORC1 signal-
ing, several studies have also proposed that YAP can function as an
upstream regulator of Akt [8,22,23]. Therefore, we next examined
the effects of SA on Akt activity as assessed by the levels of
threonine 308 phosphorylated Akt [P-Akt(T308)]. Our results
demonstrated that SA induces a signiﬁcant increase in the amount
of P-Akt(T308) and the temporal nature of this event was
remarkably similar to effects of SA on YAP expression (Fig. 1).
Indeed, these two events revealed a very high correlation
co-efﬁcient (r2 = 0.9785) (Fig. 1C). A similar correlation
co-efﬁcient (r2 = 0.931) was also found between the SA-induced
increase in YAP expression and total Akt levels (data not shown).
These strong correlations suggest that the SA-induced increase in
YAP expression might play a role in a pathway through which SA
regulates the expression of Akt and its overall activity.3.2. The overexpression of YAP induces hypertrophy through an
mTORC1-independent mechanism
In the next series of experiments we set out to determine
whether an increase in the expression of YAP would be sufﬁcient
Fig. 1. The effect of synergist ablation on YAP, Akt and c-Myc, and mTORC1 signaling. Plantaris muscles were subjected to synergist ablation (SA) and then collected either
immediately (0 day) or up 14 days after the onset of SA. (A) The muscles were subjected to Western blot analysis with the indicated antibodies and then the Western blot
membranes were stained with Coomassie blue to verify equal loading of protein in all lanes. (B) The mean time course data for the phosphorylated to total ratio (P/T) of
p70S6k1, and the amounts of phosphorylated Akt [P-Akt(T308)] and YAP. (C) Correlation between the SA-induced changes in YAP and P-Akt(T308). All values are expressed as a
percentage of the mean value obtained in the control (0 day) samples and are reported as the mean + S.E.M., n = 3–8/group. ⁄Signiﬁcantly different from 0 day, P 6 0.05.
Fig. 2. Overexpressed YAP is transcriptionally active. Mouse TA muscles were co-
transfected with HA-tagged YAP, or GFP as a control, as well as a TEAD binding
element ﬁreﬂy (FF) luciferase reporter containing 8 GGAATG binding motifs (GT-IIC
FF), and the pRL-SV40 Renilla (Ren) luciferase reporter. At 72 h post-transfection,
the muscles were collected and FF and Ren luciferase activities were measured with
a dual-luciferase assay. Measurements of the relative light units produced by FF
luciferase were normalized to that produced by Ren luciferase and this ratio is
expressed as a percentage of the values obtained from the GFP transfected muscles.
Values are reported as the mean + S.E.M., n = 3–5/group. ⁄Signiﬁcantly different
from the values obtained in GFP-transfected muscles.
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through mTORC1 would be necessary for this event. To accomplish
this, we used electroporation to transfect mouse TA muscles with
HA-tagged YAP. As shown in Fig. 2, our electroporation procedure
enabled us to robustly overexpress YAP. Furthermore, we per-
formed experiments in which TAmuscles were co-transfected with
YAP and a GT-IIC luciferase reporter construct that contains 8 TEAD
binding motifs (GGAATG) from the simian virus 40 (SV40) enhan-
cer [4]. As shown in Fig. 2, the results from these experiments
revealed that the overexpression of YAP induced a dramatic
increase in the activity of the TEAD binding reporter, thus conﬁrm-
ing that the overexpressed YAP was transcriptionally active.
Next we transfected TA muscles with YAP, or LacZ as a control
condition, and then treated the mice with daily injections of rapa-
mycin or the solvent vehicle. After 7 days, the muscles were col-
lected and the CSA of the transfected and non-transfected ﬁbers
were analyzed. As shown in Fig. 3, the results from these analyses
demonstrated that the overexpression of YAP was sufﬁcient to
induce hypertrophy (Fig. 3C and G). However, in contrast to our
hypothesis, the hypertrophic effect of YAP was not prevented
when the mice were treated with rapamycin (Fig. 3D and G).
Therefore, to conﬁrm the efﬁcacy of the rapamycin treatment,
we performed an additional experiment in which TA muscles were
transfected with Rheb. Previous studies have shown that Rheb can
directly bind and activate mTORC1 [13,24], and as shown in
Fig. 3E and G, the overexpression of Rheb induced a robust hyper-
trophic response. Moreover, the hypertrophic effect of Rheb was
effectively abolished when the mice were treated with
rapamycin (Fig. 3F and G). These results conﬁrmed the effective-
ness of our rapamycin treatment and provide further evidence that
YAP induces hypertrophy through an mTORC1-independent
mechanism.3.3. The effect of YAP on MyoD, c-Myc and MuRF1 promoter activity,
and on Smad2/3 transcriptional activity
To gain further insight into the potential mechanism(s) that are
responsible for the hypertrophic effect of YAP, we measured the
Fig. 3. The overexpression of YAP induces hypertrophy through an mTORC1-independent mechanism. Mouse TA muscles were transfected with LacZ as a control (A and B),
HA-tagged YAP (C and D) or YFP-tagged Rheb (E and F). Immediately after transfection, the mice were given daily injections of a solvent vehicle (A, C, and E) or 1.5 mg/kg
rapamycin (RAP) (B, D, and F). Muscles were collected at 7 days post-transfection and subjected to immunohistochemistry for laminin (red) and LacZ, HA or YFP (green). (A–F)
Representative merged images of Laminin and (A and B) LacZ, (C and D) HA-YAP, or (E and F) YFP-Rheb. The CSA of the transfected ﬁbers and non-transfected ﬁbers were
measured and expressed relative to the mean value obtained for the non-transfected ﬁbers in each muscle. Histograms represent the relative CSA for the transfected ﬁbers
(green bars) and non-transfected ﬁbers (black bars) obtained in each group (n = 363–645 transfected and n = 440–645 non-transfected ﬁbers/group). (G) The graph represents
the average relative CSA of the transfected ﬁbers that was obtained in each group. Values are reported as the mean + S.E.M., n = 363–645 ﬁbers (4–5 muscles)/group.
⁄Signiﬁcantly different from the drug-matched (vehicle or RAP) LacZ transfected ﬁbers, P 6 0.05. Scale bars in the images represent a length of 50 lm.
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potential to regulate skeletal muscle mass. For example, the myo-
genic regulatory factor, MyoD, is a potential positive regulator of
skeletal muscle mass and the MyoD promoter contains an MCAT
element [25,26]. Thus, we examined whether the overexpression
of YAP was sufﬁcient to activate the MyoD promoter activity and
found that this was indeed the case (Fig. 4A). Based on this obser-
vation, we propose that an increase in MyoD expression may con-
tribute to the hypertrophic effects of YAP.
c-Myc is another regulator of cell growth and, as mentioned
above, recent studies have shown that the expression of c-Myc is
positively regulated by YAP [16–21]. Therefore, we examined
whether the overexpression of YAP was sufﬁcient to induce an
increase in the activity of a c-Myc promoter construct (c-Myc Del
1; [27]). The results indicated that the overexpression of YAP
induced a 5-fold increase in c-Myc promoter activity (Fig. 4B).
Thus, an increase in the expression of c-Myc might also play a role
in pathway through which YAP induces hypertrophy.
Skeletal muscle mass is, in part, regulated by the rate of protein
degradation. Protein degradation can be regulated by several pro-
teolytic pathways including the ubiquitin proteasome system
(UPS) that involves E3 ligase enzymes that ubiquitinate and targetproteins for degradation [28]. Recently, YAP overexpression was
found to inhibit the expression of the muscle speciﬁc E3 ligase,
atrogin-1, in myoblasts [29]. This ﬁnding suggests that YAP may
have the potential to suppress protein degradation. We therefore
examined whether YAP would be sufﬁcient to decrease the pro-
moter activity of another prominent muscle speciﬁc E3 ligase,
MuRF1. As shown in Fig. 4B, MuRF1 promoter activity was signiﬁ-
cantly reduced in muscles that had been transfected with YAP
(Fig 4C). Hence, a decrease in E3 ligase expression/protein degrada-
tion could also contribute to the mechanism through which YAP
induces hypertrophy.
Finally, recent studies have shown that myostatin/TGF-b/activi
n-mediated Smad2/3 signaling contributes to the regulation of pro-
tein degradation and skeletal muscle mass, and these effects are
exerted, at least in part, through the up regulation of E3 ligase
expression [30,31]. Moreover, it has been shown that YAP can bind
to Smad7. The YAP/Smad7 interaction facilitates Smad7’s recruit-
ment to activated TGF-b receptors and subsequently results in
the inhibition TGF-b-induced Smad signaling [32]. Hence, a
decrease in Smad2/3 transcriptional activity could potentially
explain how YAP promotes a decrease in E3 ligase expression
and induces an increase in muscle mass. Therefore, to examine this
Fig. 4. YAP activates the MyoD and c-Myc promoters, inhibits the MuRF1 promoter
and inhibits Smad 2/3 transcriptional activity. Mouse TA muscles were co-
transfected with HA-tagged YAP, or GFP as a control, as well as the pRL-SV40
Renilla (Ren) luciferase reporter, and either the (A) MyoD (B) c-Myc or (C) MuRF1
promoter, or a (D) Smad binding element (SBE) ﬁreﬂy (FF) luciferase reporter. At
72 h post-transfection, the muscles were collected and FF and Ren luciferase
activities were measured with a dual-luciferase assay. Measurements of the relative
light units produced by FF luciferase were normalized to that produced by Ren
luciferase and this ratio was expressed as a percentage of the values obtained in the
GFP transfected muscles. Values are reported as the mean + S.E.M., n = 3–4/group.
⁄Signiﬁcantly different from the GFP-transfected muscles, P 6 0.05.
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binding element (SBE) luciferase reporter construct which contains
12 Smad CAGA binding motifs. As shown in Fig. 4D, our results
indicated that the overexpression of YAP induced a 85% decrease
in the activity of the SBE reporter. This ﬁnding highlights the
potential existence of a pathway through which an increase in
the expression of YAP leads to the inhibition of Smad2/3 activity,
subsequent E3 ligase expression, and ultimately an increase in
muscle mass.
4. Discussion
This is the ﬁrst skeletal muscle-based study to demonstrate that
the expression of YAP is elevated in response to increased mechan-
ical loading. Given YAP’s role in the regulation of cellular growth,
this ﬁnding suggests that YAP might contribute to the pathway
through which increased mechanical loading induces an increase
in muscle mass. However, in contrast to our original hypothesis,
we did not ﬁnd a simple relationship between the load-induced
changes in YAP expression and the activation of mTORC1 signaling.
This ﬁnding implies that load-induced changes in YAP expression
are unlikely to be the main factor responsible for, at least the ini-
tial, mechanical activation of mTORC1. Interestingly though, we
did ﬁnd a very strong correlation between the changes in expres-
sion of YAP and that of both P-Akt(T308) and total Akt. Thus,
changes in the expression of YAP might contribute to the mechan-
ical regulation of Akt expression and its activity. Alternatively, a
separate mechanically-sensitive factor might simultaneously up
regulate the expression of both YAP and Akt. Recently, it was
reported that YAP might actually be located downstream of
mTORC1, with mTORC1 regulating YAP protein levels by inhibiting
its autophagy-mediated degradation [33]. Thus, by attenuating
autophagy-mediated turnover, the initial mechanical activation
of mTORC1 might promote the more delayed increase in expres-
sion. This hypothesis is supported by recent evidence that suggests
that autophagy may indeed be inhibited during SA-induced over-
load [34]. Further work is therefore required to explore thepotential relationship between mTORC1 activity and YAP protein
expression, and to determine whether YAP is necessary for
overload-induced muscle hypertrophy.
In addition to the overload-induced increase in total YAP, we
also show for the ﬁrst time that SA induces an increase in YAP
S112 phosphorylation. This novel ﬁnding suggests that the Hippo
signaling pathway, and in particular the Lats1/2 kinases, are sensi-
tive to mechanical stimuli in skeletal muscle in vivo. The reason for
the increase in Hippo pathway signaling is unclear; however, given
the recent evidence that constitutive activation of YAP results in
muscle atrophy and myopathy [35], activation of the Hippo path-
way may, in part, be an attempt to limit the magnitude of the
increase in YAP transcriptional activity that would occur with the
SA-induced increase in total YAP protein.
In this study, we have also shown that a transient overexpres-
sion of YAP is sufﬁcient to induce muscle hypertrophy.
Surprisingly, however, we discovered that the hypertrophic effect
of YAP was mediated by an mTORC1-independent mechanism.
Hence, to gain further insight into how YAP induces hypertrophy,
we measured the effect of YAP on various molecules that have been
implicated in the regulation of muscle mass. The results from these
analyses led to the identiﬁcation of several candidate mechanisms.
For instance, we obtained evidence which indicates that the over-
expression of YAP induces an increase in the expression of c-Myc.
Since c-Myc is a potent activator of ribosome biogenesis, a
YAP-induced increase in c-Myc expression might contribute to
the hypertrophic response by enhancing rates of protein synthesis
via an increase in translational capacity. Consistent with this
hypothesis, a recent study in myoblasts demonstrated that consti-
tutively active YAP promotes an increase in the expression of genes
involved in ribosome biogenesis and assembly [29]. We also found
that YAP promoted an increase in MyoD promoter activity. MyoD is
a myogenic regulatory factor that plays an important role in satel-
lite cell activation and proliferation [36]; however, its role in differ-
entiated muscle cells is less clear. Nonetheless, it has been shown
that, in adult skeletal muscle, the overexpression of MyoD can
induce muscle ﬁber hypertrophy [26]. Thus, when combined, our
results suggest that increases in c-Myc and MyoD expression might
contribute to the pathway through which YAP induces muscle
hypertrophy. While promising, additional studies will be needed
to determine if YAP promotes an increase in the mRNA and protein
levels of c-Myc and MyoD, and whether these effects are required
for the hypertrophic effects of YAP.
Our results also indicate that YAP markedly reduces Smad2/3
transcriptional activity which, in skeletal muscle, is stimulated by
the myostatin/TGF-b/activin receptors [37]. Importantly, YAP has
been shown to facilitate the recruitment of inhibitory Smad7 to
activated TGF-b receptors [32], and this might explain how YAP
inhibited Smad2/3 transcriptional activity. In addition, YAP has
also been reported to increase the expression of Follistatin-like 3,
a negative regulator of myostatin signaling [29,38], and increase
BMP4 expression which can inhibit Smad2/3 activity by stimulat-
ing an increase in the competitive Smad1/5/8 signaling network
[29,37]. Whether individually, or combined, it is likely that the
aforementioned mechanisms contribute to the YAP-mediated
reduction in Smad2/3 signaling. Importantly, a decrease in
Smad2/3 signaling also has the potential to regulate skeletal mus-
cle mass by inhibiting the expression of UPS E3 ligases. Indeed, in
this study we found a YAP-mediated decrease in MuRF1 promoter
activity. Furthermore, it has previously been shown that the over-
expression of constitutively active YAP inhibits E3 ligase atrogin-1
mRNA expression in myoblasts [29]. Interestingly, Baehr et al. [15]
recently reported that the SA-induced response of MuRF1 and
atrogin-1 mRNA follows a pattern that is the inverse of our
reported changes of YAP protein, suggesting the possibility that
YAP could play a role in inhibiting the expression of MuRF1 (and
1496 C.A. Goodman et al. / FEBS Letters 589 (2015) 1491–1497atrogin-1) expression under these conditions. In turn, a
YAP-mediated inhibition of MuRF1 (and possibly atrogin-1)
expression may play a role in limiting the overall SA-induced
increase in ubiquitin proteasome-mediated protein degradation
and/or limiting the ubiquitination and subsequent degradation of
protein targets speciﬁc to just these particular E3 ligases.
Regardless, our ﬁndings suggest that the overexpression of YAP
may induce muscle hypertrophy, in part, by suppressing rates of
protein degradation via the inhibition of Smad-mediated E3 ligase
expression. Additional studies are, however, required to further
explore the role of YAP in the regulation of Smad-mediated signal-
ing and protein degradation in skeletal muscle.
Our ﬁnding that the overexpression of YAP was sufﬁcient to
induce muscle hypertrophy appears to stand in stark contrast to
a previous study that found that the overexpression of YAP induced
muscle atrophy and signs of myopathy [35]. It is important to point
out, however, that the YAP used in the study by Judson et al. [35]
was a constitutively active YAP mutant that was overexpressed
for 5–7 weeks. Taken together, this suggests that although the con-
stant and prolonged activation YAP-mediated signaling is eventu-
ally deleterious to skeletal muscle, the relatively shorter term
activation, perhaps in a pulsatile manner, could be a promising
strategy for increasing muscle mass and/or preventing muscle
atrophy. Further studies, are needed to explore this possibility.
An important question raised by this study is that: if an increase
in the expression of YAP induces hypertrophy through an
mTORC1-independent mechanism, and mechanical overload
induces hypertrophy via an mTORC1-dependent mechanism
[10,39], then what role, if any, does the increase in YAP play in
mechanically-overloaded muscles? The answer to this question is
not known, but one possibility is that the SA-induced increase in
YAP occurs speciﬁcally within satellite cells, which in turn, would
promote an increase in muscle ﬁber number, but not necessarily
hypertrophy. In support of this possibility it has been shown that
satellite cells are necessary for an overload-induced increase in
muscle ﬁber number (i.e., hyperplasia), but they are not required
for overload-induced muscle ﬁber hypertrophy [10,40].
Moreover, it has been shown that YAP is elevated in activated
satellite cells and that an increase in YAP signiﬁcantly contributes
to the regulation of myogenesis [29,41]. Thus, increased YAP
expression in satellite cells may result in cell proliferation, while
an increase in YAP in the mature differentiated muscle ﬁbers
appears to result in hypertrophy. Clearly, further work will be
needed to identify the cellular location(s) of the
overload-induced increase in YAP, and whether YAP is necessary
for both overload-induced hyperplasia and hypertrophy.
Finally, during the preparation of this manuscript, Watt et al.,
published a study that investigated the role of YAP in the regula-
tion of muscle ﬁber size [42], and their results are consistent with
our data which indicate that the overexpression of YAP induces
hypertrophy. Speciﬁcally, Watt et al., analyzed muscles after a
more prolonged (4 wk) and viral-mediated overexpression of
YAP, and they found that the overexpression of YAP induces hyper-
trophy while having no effect on markers of mTORC1 signaling
[42]. Furthermore, they demonstrated that the hypertrophic effects
of YAP are associated with an increase in the rates of protein syn-
thesis [42]. This latter observation is particularly noteworthy
because it provides support for our proposal that YAP may increase
protein synthesis, in part, through a c-Myc-mediated increase in
ribosome biogenesis. However, in contrast to our ﬁndings, Watt
et al., concluded that the overexpression of YAP does not lead to
a signiﬁcant reduction in E3 ligase expression. This apparent dis-
crepancy may be due differences in the time point examined after
YAP transfection (3 d vs 4 wk), leaving open the possibility that E3
ligase expression may have been suppressed at earlier time points.
Unfortunately, Watt et al., did not examine the effect of YAP onSmad signaling, nor did they examine the effect of increased
mechanical loading on YAP expression. Nonetheless, our ﬁndings
are largely congruent with theirs and, importantly, we extend their
ﬁndings by showing that increased mechanical loading induces the
expression of YAP, but this effect is not associated with the initial
mechanical activation of mTORC1. Moreover, we have provided
novel insights into the potential mechanisms through which YAP
may induce hypertrophy. Thus, our study provides new informa-
tion on how YAP may exert its growth stimulating effect and this
information could lead to the identiﬁcation of novel molecules/-
pathways that regulate skeletal muscle mass.
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